라이프
전체기사 보기-
Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year
HANGZHOU, China, Aug. 20, 2025 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% year-over-year (YoY) to RMB 482 million, while net profit surged by 76.0% to exceed RMB 121 million, representing a net profit margin of 25.1%. In the first half of 2025, Zylox-Tonbridge maintained solid performance in its core neurovascular and peripheral vascular intervention businesses
- 김갑성 기자
- 2025-08-20 21:41
-
Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
SHANGHAI, Aug. 20, 2025 -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" in Cell Stem Cell, featured as a cover story. This study marks the first establishment of a technique to efficiently and directionally differentiate human pluripotent stem cells (hPSCs) into A10 subtype dopamine neurons. This breakthrough lays a critical scientific foundation for cell therapy of psychiatr
- 김갑성 기자
- 2025-08-20 20:49
-
Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth
HONG KONG, Aug. 20, 2025 -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained high growth and improved profitability during the reporting period, with core business development and continuous advancement in its medical AI capabilities. In terms of financial performance, the Company recorded revenue of RMB2.5 billion during the period, representing a year-on-year increase of
- 김갑성 기자
- 2025-08-20 19:19
-
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer
HONG KONG, Aug. 20, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study represents the third Phase III trial for cadonilimab in gastric cancer. The study aims to improve the radical resectio
- 김갑성 기자
- 2025-08-20 16:11
-
DKSH Healthcare Establishes Industry Benchmark in Carbon Emissions Tracking in Thailand
DKSH Business Unit Healthcare has reached a significant milestone in building a more sustainable healthcare supply chain by successfully tracking carbon emissions across its value chain through a collaboration with UOB FinLab's GreenTech Accelerator and Smart Tradzt in Thailand. This achievement also marks the implementation of a reusable cold-chain packaging solution. The initiative underscores DKSH Healthcare's ongoing commitment to environmental responsibility and its proactive approach to advancing sustainable business practices. BANGKOK, Aug. 20, 2025 -- DKSH Business Unit
- 김갑성 기자
- 2025-08-20 12:00
-
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
BEIJING, Aug. 20, 2025 -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in precision diagnostics and treatment. The Photon Counting Detectors (PCD), as the core technology of PCCT, differ significantly from traditional Energy Integratin
- 김갑성 기자
- 2025-08-20 10:45
-
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using Xta
- 김갑성 기자
- 2025-08-20 08:00
-
ARC Therapies Advances Gut Microbiome Research with YB328 Toward Clinical Application
[ 메디채널 김갑성 기자 ] Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 20, 2025 -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials to evaluate its administration methods and therapeutic e
- 김갑성 기자
- 2025-08-20 07:00
-
Ping An Good Doctor (1833.HK) Reports Strong Interim Results: Revenue and Profit Accelerate as AI Fuels New Growth Momentum
HONG KONG, Aug. 19, 2025 -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025. During the first half of 2025, the Company delivered steady operational performance, showcasing strong growth momentum with gains in both revenue and profitability. Total revenue reached RMB2.5 billion, an increase of 19.5% year-on-year, while net profit attributable to shareholders rose to RMB134 million, an increase of 136.8% year-on-year. Notably, revenue from the
- 황정호 기자
- 2025-08-19 23:11
-
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
SHANGHAI, Aug. 19, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables the initiation of Phase I/II study of 7MW4911 to evaluate the safety, pharmacokinetics, and efficacy in patients with advanced colorectal cancer and other advanced gastrointestinal tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly
- 김갑성 기자
- 2025-08-19 22:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
- IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 01시 40분